Police COVID-19 Serosurvey (PoliCOV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04643444|
Recruitment Status : Recruiting
First Posted : November 25, 2020
Last Update Posted : December 28, 2020
|Condition or disease||Intervention/treatment|
|SARS-CoV-2 Infection Volunteers Healthy||Diagnostic Test: Blood sampling Other: Online Questionnaire|
i) To determine the extent of infection with seroprevalence data in the special population of police officers of the canton Bern.
ii) To determine risk factors for infection by comparing the proportion of seropositivity (infected versus noninfected individuals). The investigators hypothesize that police officers with fieldwork activity will have a higher seroprevalence than will office and administration personnel. The investigators hypothesize that working in the city of Bern will be associated with a higher seroprevalence than will working in other geographic areas of the canton (i.e. rural area).
iii) To monitor COVID-19 antibody titres and neutralizing capacity over time and to associate them with reinfection rates and infection-free intervals in police officers after accidental contact with a proven COVID-19 case. The investigators hypothesize that in seropositive individuals, there will be a decreasing dynamic of antibody titres over the one-year study period, and hence, a decrease of neutralizing capacity.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland|
|Estimated Study Start Date :||January 2021|
|Estimated Primary Completion Date :||January 2022|
|Estimated Study Completion Date :||June 2022|
- Diagnostic Test: Blood sampling
Testing for the presence of SARS-CoV-2 antibodies
- Other: Online Questionnaire
Questions on working place, risk profiles and PPE
- Seroprevalence [ Time Frame: One year ]The variable of primary interest is COVID-19 seropositivity. This variable is measured at five time points over the one-year study period. The following baseline factors may have an influence on the primary endpoint and will be obtained: (i) pre-existing comorbidities, (ii) rural versus city distribution of working place, and (iii) office work versus field work.
- Risk profile assessment [ Time Frame: One year ]The investigators will assess the proportion of symptomatic and asymptomatic cases among seropositive participants. The investigators will calculate the attack rate in different subgroup. These include (i) study participants with health-related risk factors (age>50 and age>60 years, diabetes, arterial hypertension, cardiovascular disease, chronic pulmonary disease, immune-compromised status due to host diseases, medical treatment, cancer, obesity), (ii) activity-related subgroups (i.e. fieldwork vs office activity), (iii) geography-related subgroups (i.e. city vs rural areas). In follow-up visits, the antibody titers (i.e. dynamic) and the neutralization capacity will be assessed. Thereby, the investigators will determine the change in serum levels of SARS-CoV-2 antibodies over time in seropositive participants.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04643444
|Contact: Parham Sendi, MDemail@example.com|
|University of Bern, Institute for Infectious Diseases||Recruiting|
|Bern, BE, Switzerland, 3010|
|Contact: Parham Sendi, MD|
|Principal Investigator:||Parham Sendi, MD||University of Bern|